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Purpose: To evaluate the clinical features, associated factors, and treatment outcomes of scleritis in the Korean 
population. 
Methods: Medical records were retrospectively reviewed for 94 eyes of 76 patients with scleritis. Clinical features of 
scleritis, including systemic disease, presence of microorganisms, serologic markers, history of previous ocular 
surgery, and use of immunosuppressants were investigated and compared amongst the subtypes of scleritis. 
Treatment outcomes were evaluated using best corrected visual acuity (BCVA) and time to scleritis remission. 
Results: Nodular scleritis was the most common form observed, followed by necrotizing scleritis with inflammation, 
diffuse scleritis, and necrotizing scleritis without inflammation, respectively. A total of 16 of 76 patients (21.1%) 
had connective tissue diseases. Eleven cases (14.5%) had infectious scleritis, of which bacteria (54.5%) and fun-
gi (45.5%) were the causative microorganisms. Thirty-three patients (43.4%) had previous ocular surgery, mostly 
pterygium excision. Notably, a history of pterygium excision was significantly associated with development of ne-
crotizing and infectious scleritis (odds ratio [OR], 399 and 10.1; p< 0.001 and 0.002, respectively). In addition, 
patients with necrotizing scleritis were more likely to have infectious scleritis (OR, 11.7; p= 0.001). BCVA after 
treatment and time to remission also showed significant differences among the different scleritis subtypes. 
Systemic immunosuppression was required in addition to steroids for treating diffuse and necrotizing scleritis. 
Conclusions: Careful taking of patient history including previous pterygium excision should be performed, especially 
in patients with necrotizing and infectious scleritis. In addition, evaluation of microbiological infection can be cru-
cial for patients with necrotizing scleritis and history of pterygium excision. 
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Scleritis is a severe ocular inflammatory disorder that is 
commonly associated with systemic collagen vascular disease. 
Previous reports have demonstrated that approximately 50% 
of patients with scleritis have systemic connective tissue dis-
eases [1-6]. However, scleritis can also be caused by ocular 
surgery, such as pterygium, cataract extraction, or strabismus 
surgeries. Although scleritis is a serious postsurgical compli-
cation [7-9], clinical characteristics of surgically-induced 
scleritis or the type of surgery associated have not been ex-
tensively investigated.
Infectious and necrotizing scleritis are two subtypes of 
scleritis with particularly poor prognoses; there are several 
cases reporting the requirement for either evisceration or 
enucleation in order to control the infection and inflammation 
in infectious and necrotizing scleritis [10]. Systemic im-
munosuppression in necrotizing scleritis and early antibiotic 
treatment in infectious scleritis are essential for preserving 
vision and preventing the spreading of infection into adjacent 
ocular structures [11]. However, predisposing factors for ear-
ly diagnosis of these two forms of scleritis have not been 
thoroughly studied. Here, we investigated the clinical char-
acteristics and predisposing factors of scleritis with respect to 
treatment course and outcome in the Korean population. 
Materials and Methods 
Medical records of patients who were diagnosed with Korean J Ophthalmol Vol.24, No.6, 2010
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Table 1. Demographics, clinical features, previous ocular surgery, and seropositive cases of scleritis
Parameters Values
Age (yr) 59.5 ± 13.8 (range, 11-81)
Gender (male : female) 23 : 53
Follow-up period (mon) 19.05 ± 34.17 (range, 1-240)
Laterality (unilateral : bilateral) 58 (76.3) : 18 (23.7)
Prevalence of subtype (nodular : diffuse:necrotizing) 31 (40.8) : 18 (23.7) : 27 (35.5)
Previous ocular surgery  33 (43.4)
     Pterygium excision 29 (38.2)
     Cataract extraction  3 (3.95)
     Strabismus surgery  1 (1.32)
Seropositivity  16 (21.1)
     Fluorescent anti-nuclear antibody 9 (11.8)
     Anti-neutrophil cytoplasmic antibody 4 (5.26)
     Rheumatoid factor  3 (3.95)
     Human leukocyte antigen-B27 1 (1.32)
     Anti-streptolysin O  1 (1.32)
     Ribonucleoprotein antibody 1 (1.32)
     Cryoglobulin 1 (1.32)
Values are presented as mean ± SD or number (%).
scleritis at Seoul National University Hospital between 
January 2005 and December 2008 were reviewed. The diag-
nosis of scleritis was made based on the presence of in-
flammation of scleral and episcleral vessels that did not 
blanch with topical phenylephrine, the presence of scleral 
thinning, edema, or nodules. Patients who did not have a fol-
low-up visit were excluded from this study. Scleritis was 
classified into the following subtypes; diffuse, nodular, and 
necrotizing scleritis with or without inflammation. Diffuse 
scleritis was characterized by the presence of scleral edema 
and redness with a tortuous vascular network. Nodular scler-
itis presented as a nodule that was firm and tender to 
palpation. Necrotizing scleritis with inflammation was de-
fined as having an avascular area of sclera with adjacent 
scleral edema and congestion while necrotizing scleritis 
without inflammation was classified for cases presenting 
with a thin and avascular area of sclera with no active neigh-
boring inflammation. Infectious scleritis was diagnosed fol-
lowing isolation of the causative microorganism from the 
lesion according to a microbiological workup. For first-line 
treatment for non-infectious nodular or diffuse scleritis with-
out any underlying systemic disease, topical and oral cortico-
steroids or systemic non-steroidal anti-inflammatory drugs 
were used. In severe cases refractory to oral corticosteroid 
therapy, systemic immunosuppressive agents such as aza-
thioprine, cyclosporine, and mycophenolate mofetil were 
used. For treatment of infectious scleritis, topical and oral an-
tibiotics or anti-fungal agents were used after a causative mi-
croorganism was isolated by culture from scleral scrapings in 
the base of active lesion [9,10].
In total, 94 eyes of 76 patients met the inclusion criteria. 
The study protocol was approved by the Institutional Review 
Board, and informed consent was obtained from patients. 
Patient medical records were retrospectively reviewed with 
respect to clinical manifestations, subtypes of scleritis, presence 
of systemic or ocular co-morbidities, and a history of previous 
ocular surgery. In addition, serologic markers and presence 
of causative microorganisms isolated from culture from cases 
of infectious scleritis were investigated. The markers included 
veneral disease research laboratory, fluorescent anti-nuclear 
antibody (FANA), anti-neutrophil cytoplasmic antibody 
(ANCA), rheumatoid factor, human leukocyte antigen-B27, 
anti-streptolysin O, and ribonucleoprotein antibody. To esti-
mate the significance of the risk factors for the development 
of infectious and necrotizing scleritis, an odds ratio was cal-
culated for each risk factor. 
To compare visual outcomes, best corrected visual acuities 
(BCVA) were evaluated based on the logarithmic value of the 
minimal angle of resolution scale at the time of diagnosis and 
after clinical remission. Additionally, the time elapsed from 
diagnosis to remission of scleritis was analyzed. Clinical re-
mission was defined as when 1) the patient complained of no 
symptoms and when 2) any sign of scleral inflammation dis-
appeared on slit-lamp examination. Both BCVA and time to 
remission were compared between seropositive and sero-
negative patients as well as infectious and noninfectious us-
ing Student’s t-test, one-way analysis of variance (ANOVA), 
and survival analysis. 
 In order to determine which factors required the use of ad-
ditional systemic immunosuppression for treating scleritis, 
patients were divided into two groups consisting of those 
who were treated with oral corticosteroids only and those 
who needed additional systemic immunosuppressants for 
resolution of the disease. The subtypes of scleritis, seroposi-
tivity, and systemic comorbidities were then compared be-
tween the two groups using Fisher’s exact test, likelihood ra-
tio test for categorical data, and Student’s t-test. 
All statistical analyses were performed using SPSS ver. SJ Ahn, et al. Scleritis in the Korean Population
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Table 2. Incidence of pterygium excision in patients with scleritis and combined connective tissue disease (CTD) at 
presentation according to scleritis subtype 
Nodular Diffuse Necrotizing p-value
*
No. of patients with previous 
pterygium excision (%)
†
2 (6.5) 1 (5.6) 26 (96.3) < 0.001
No. of patients with CTD (%)
† 9 (29.0) 5 (27.8) 2 (7.4) < 0.001




Juvenile rheumatoid arthritis (1)
Behcet’s disease (1)









N/A = not applicable.
*p-value was obtained by Fisher exact test; 
†The percentage was calculated among the patients with one subtype of scleritis.
Fig. 1. Visual acuities before and after treatment. Patients with in-
fectious necrotizing scleritis had the poorest best corrected visual 
acuities (BCVA) before and after treatment. The data are presented 
as the mean ± standard deviation. logMAR= logarithmic value of 
the minimal angle of resolution.
15.0 (SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was 
considered statistically significant. 
Results 
Demographic data are summarized in Table 1. Scleritis 
was more than twice as times prevalent in females than males 
(male:female = 23:53), and 76.3% of the cases were 
unilateral. The most common subtype of scleritis was nod-
ular scleritis (40.8%), followed by necrotizing scleritis with 
inflammation (27.6%), diffuse scleritis (23.7%), and necrot-
izing scleritis without inflammation (7.89%). Associated 
clinical factors are shown in Table 1. Sixteen patients 
(21.1%) were seropositive, most commonly FANA-positive 
(n = 9). Notably, 33 out of 76 patients (43.4%) had pre-
viously ocular surgeries, of which 29 cases were pterygium 
excision. Of note was a high association between a history of 
pterygium surgery and the development of necrotizing or in-
fectious scleritis. Specifically, most of the patients with ne-
crotizing scleritis (96.3%) had a previous history of ptery-
gium surgery; however, only 3 of 49 patients (6.1%) with 
non-necrotizing scleritis had a prior pterygium excision. 
Additionally, 89.3% of scleritis cases with a history of ptery-
gium excision were necrotizing scleritis. The odds ratio for a 
history of pterygium excision was 399 in patients with ne-
crotizing scleritis compared to those with non-necrotizing 
scleritis (95% confidence interval [CI], 39.4-4,030; p <
0.001). In addition, 9 out of 11 patients (81.8%) with in-
fectious scleritis had a history of prior pterygium surgery. 
The odds ratio for a history of pterygium excision was 10.1 in 
infectious scleritis compared to noninfectious scleritis (95% 
CI, 2.00-51.2;  p =0 . 0 0 2 ) .  
Moreover, a significant association between necrotizing 
and infectious scleritis was observed. Specifically, of the 11 
patients with infectious scleritis, 9 (88.8%) were diagnosed 
with necrotizing scleritis, which resulted in an odds ratio for 
infectious scleritis of 11.8 for patients with necrotizing com-
pared to non-necrotizing scleritis (95% CI, 2.31-59.7; p =
0.001). Thus, necrotizing scleritis was significantly asso-
ciated with infectious scleritis and a history of pterygium 
surgery.
Sixteen patients (21.1%) had connective tissue diseases. 
The percentage of associated connective tissue diseases was 
different among the subtypes of scleritis (Table 2). In addi-
tion, diffuse and nodular scleritis was associated with co-
morbidity of connective tissue disease, although statistical 
significance was borderline (p = 0.07). Rheumatoid arthritis 
was the most common connective tissue disease associated 
with scleritis. 
Eleven eyes (14.5%) were diagnosed as having infectious 
scleritis. Bacterial infection comprised 54.5% (n = 6) of these 
cases, followed by fungi (n = 5, 45.5%) and viruses (n = 1, 
9.09%). Pseudomonas was the most common pathogen (3 
cases), followed by Fusarium and Stenotrophophilia (2 cases). 
Haemophilus, Acromobacter, Aspergillus, Beauveria, Candida, Korean J Ophthalmol Vol.24, No.6, 2010
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Table 3. Comparison of clinical factors between patients treated with oral steroids only and those treated with steroids 





Age (yr) 57.0 ± 13.3 63.8 ± 12.7 0.099
*
Gender (male : female)   3:12  12:19 0.176
†
Laterality (unilateral : bilateral) 12:3  25:6 0.624
†
Prevalence of subtype (nodular : diffuse:necrotizing) 9:2:4 7:10:14 0.043
‡
Seropositivity 3 9 0.392
†
Connective tissue disease 2 6 0.478
†
*p-value was obtained by Student’s t-test; 
†Fisher’s exact test; 
‡Likelihood ratio test, respectively.
Fig. 2. Survival curves of remission. A significant difference in remission was observed (p = 0.028) among the different scleritis subtypes. No
significant difference was seen between infectious versus noninfectious, and seropositive versus seronegative cases. The y-axis indicates the 
proportion of cases with persistent scleritis as calculated by the following equation: (1 – the proportion of remission).
and herpes zoster were also isolated. There were two cases of 
coinfections; one was coinfection of Pseudomonas and Candida, 
and the other was coinfection of Stenotrophophilia and 
Acromobacter. Two eyes with fungal scleritis were eviscer-
ated because of uncontrolled infection that eventually pro-
gressed into endophthalmitis.
To evaluate visual outcome according to subtypes of scler-
itis, BCVA was investigated at the time of diagnosis and after 
remission (Fig. 1). BCVA at the time of diagnosis was worse 
in patients with infectious and necrotizing scleritis than patients 
with nodular and diffuse scleritis. Patients with infectious 
scleritis had the worst BCVA after remission (1.19 ± 1.11), 
followed by non-infectious necrotizing (0.538 ± 0.457), nod-
ular (0.367 ± 0.637), and diffuse scleritis (0.282 ± 0.506). 
These differences in visual acuities among subtypes of scler-
itis were statistically significant (p = 0.013 at the time of di-
agnosis and 0.008 after remission; one-way ANOVA). 
The median time to resolution was significantly longer in 
necrotizing scleritis (10 months, p = 0.028; log rank test), 
compared to diffuse (7 months) and nodular subtypes (7 
months) (Fig. 2). The median time to resolution of infectious 
scleritis was longer than non-infectious type (10 months vs. 8 
months); however, this difference was not statistically sig-
nificant (p = 0.166). There was no difference in the median 
time to resolution between seropositive and seronegative 
scleritis (p =0 . 7 3 2 ) .  
In order to determine the factors associated with the use of 
additional systemic immunosuppression, we analyzed the 
clinical characteristics between the patients who were treated 
with conventional oral corticosteroids and the patients who 
needed additional systemic immunosuppressants because of 
inflammation refractory to systemic steroids (Table 3). We 
found that patients with diffuse and necrotizing scleritis were 
more likely to require systemic immunosuppression (p = 
0.043, likelihood ratio test).   
Discussion 
A noticeable finding of this study was that patients with ne-
crotizing scleritis were more likely to have had previous 
pterygium excision and infectious scleritis. This finding is 
consistent with the report by O'Donoghue [8], who
 demon-
strated a high association between necrotizing and surgi-
cally-induced scleritis. The association between a history of 
pterygium excision and two destructive subtypes of scleritis 
(necrotizing and infectious) might suggest a role for ptery-
gium excision as either a causative or inducing factor of the 
two types of scleritis. This hypothesis can be explained by 
the previously suggested proposal that surgical techniques or 
intra- or postoperative medications for pterygium excision 
might predispose inflammation and necrosis of the sclera and 
make ocular tissue vulnerable to infection [12]. In addition, it SJ Ahn, et al. Scleritis in the Korean Population
335
is possible that the use of mitomycin C during pterygium sur-
gery may induce necrotizing and infectious scleritis. 
For successful treatment of scleritis patients, early dis-
crimination between noninfectious autoimmune scleritis and 
infectious scleritis is important since the treatment regimens 
for infectious scleritis, antibiotics, is contrary to the treat-
ment for non-infectious necrotizing scleritis, which consists 
of systemic immunosuppressants. However, the differential 
diagnosis between necrotizing scleritis with and without in-
fection is often difficult. Indeed, two patients in our study 
whose eyes were eviscerated because of uncontrolled fungal 
scleritis were initially misdiagnosed as having an im-
mune-mediated necrotizing scleritis and were initially treat-
ed with topical and systemic immunosuppressants. Given 
that pterygium excision was a significant factor associated 
with both necrotizing and infectious scleritis, careful exami-
nation for signs of infection and microbiological work-up 
should be performed, especially in patients who present with 
scleral necrosis.
Another remarkable finding of this study was that fungal 
infection comprised of almost half cases of infectious scler-
itis in our study. Indeed, the proportion of fungal scleritis in 
the present study was substantially higher than previously re-
ported [9,10,13]. This may be because of a geographic differ-
ence of an infectious pathogen in scleritis as reported in pre-
vious studies [9,10,13].
 The prognosis of fungal scleritis in 
this study was poor, as previously reported [14-18].
As shown in the present study, visual outcome depended 
on the subtypes of scleritis. Nodular or diffuse scleritis 
showed better visual acuity both at the time of diagnosis and 
after remission. Necrotizing scleritis, especially when asso-
ciated with infectious scleritis, demonstrated poor visual 
acuity both at the time of diagnosis and after remission. In ad-
dition, patients with necrotizing scleritis had a prolonged du-
ration of disease. Furthermore, patients with non-infectious 
necrotizing scleritis were more likely to require systemic im-
munosuppressants in addition to conventional oral steroids 
for treatment, compared to those with nonnecrotizing 
scleritis. An association between the use of additional im-
munosuppressants and other clinical factors such as ANCA, 
which was reported in previous studies [19], was not found in 
this study. 
In conclusion, the results of this study suggest that a his-
tory of pterygium excision in scleritis is a significant factor 
associated with poor prognosis due to the strong association 
with necrotizing and infectious scleritis. Hence, when pa-
tients with a history of pterygium surgery present with ne-
crotizing scleritis, immunosuppressants should be cautiously 
started after excluding the possibility of an infection by a 
thorough microbiological work-up. 
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